169 related articles for article (PubMed ID: 14560055)
21. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
[TBL] [Abstract][Full Text] [Related]
22. New protein steals the show as 'costimulator' of T cells.
Cohen J
Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
[No Abstract] [Full Text] [Related]
23. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
[TBL] [Abstract][Full Text] [Related]
24. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.
Chai JG; Vendetti S; Amofah E; Dyson J; Lechler R
J Immunol; 2000 Sep; 165(6):3037-42. PubMed ID: 10975813
[TBL] [Abstract][Full Text] [Related]
25. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
26. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.
Krummel MF; Sullivan TJ; Allison JP
Int Immunol; 1996 Apr; 8(4):519-23. PubMed ID: 8671638
[TBL] [Abstract][Full Text] [Related]
27. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
28. Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens.
Yi-qun Z; Joost van Neerven RJ; Kasran A; de Boer M; Ceuppens JL
Int Immunol; 1996 Jan; 8(1):37-44. PubMed ID: 8671587
[TBL] [Abstract][Full Text] [Related]
29. Could expression of co-stimulatory molecules on B-PBL condition the acceptance or rejection of human liver grafts?
Minguela A; Sánchez-Bueno F; Marín L; Miras M; Pons JA; Muro M; Torío A; García-Alonso AM; Robles R; Parrilla P; Ramirez P; Alvarez-López MR
Transplant Proc; 2001; 33(1-2):1384-5. PubMed ID: 11267338
[No Abstract] [Full Text] [Related]
30. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.
Truneh A; Reddy M; Ryan P; Lyn SD; Eichman C; Couez D; Hurle MR; Sekaly RP; Olive D; Sweet R
Mol Immunol; 1996 Feb; 33(3):321-34. PubMed ID: 8649453
[TBL] [Abstract][Full Text] [Related]
31. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80.
Boulougouris G; McLeod JD; Patel YI; Ellwood CN; Walker LS; Sansom DM
J Immunol; 1998 Oct; 161(8):3919-24. PubMed ID: 9780158
[TBL] [Abstract][Full Text] [Related]
32. Differential requirement for CD28/CTLA-4-CD80/CD86 interactions in drug-induced type 1 and type 2 immune responses to trinitrophenyl-ovalbumin.
Nierkens S; Aalbers M; Bol M; Bleumink R; van Kooten P; Boon L; Pieters R
J Immunol; 2005 Sep; 175(6):3707-14. PubMed ID: 16148116
[TBL] [Abstract][Full Text] [Related]
33. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.
Freeman GJ; Cardoso AA; Boussiotis VA; Anumanthan A; Groves RW; Kupper TS; Clark EA; Nadler LM
J Immunol; 1998 Sep; 161(6):2708-15. PubMed ID: 9743327
[TBL] [Abstract][Full Text] [Related]
34. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
35. Structure of murine CTLA-4 and its role in modulating T cell responsiveness.
Ostrov DA; Shi W; Schwartz JC; Almo SC; Nathenson SG
Science; 2000 Oct; 290(5492):816-9. PubMed ID: 11052947
[TBL] [Abstract][Full Text] [Related]
36. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1.
Tan P; Anasetti C; Hansen JA; Melrose J; Brunvand M; Bradshaw J; Ledbetter JA; Linsley PS
J Exp Med; 1993 Jan; 177(1):165-73. PubMed ID: 7678111
[TBL] [Abstract][Full Text] [Related]
37. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
38. In silico engineering a CD80 variant with increased affinity to CTLA-4 and decreased affinity to CD28 for optimized cancer immunotherapy.
Hajihassan Z; Afsharian NP; Ansari-Pour N
J Immunol Methods; 2023 Feb; 513():113425. PubMed ID: 36638881
[TBL] [Abstract][Full Text] [Related]
39. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.
Murata K; Dalakas MC
Am J Pathol; 1999 Aug; 155(2):453-60. PubMed ID: 10433938
[TBL] [Abstract][Full Text] [Related]
40. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley PS; Greene JL; Tan P; Bradshaw J; Ledbetter JA; Anasetti C; Damle NK
J Exp Med; 1992 Dec; 176(6):1595-604. PubMed ID: 1334116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
